Future Directions in Anxiety Research

  • C. Bræstrup
  • E. B. Nielsen
Conference paper
Part of the Psychopharmacology Series book series (PSYCHOPHARM, volume 5)


More than 3.5 million patients suffer from anxiety in the United States of America alone. While our knowledge of the basic biological mechanisms of anxiety is very poor, we have a good understanding of the mechanism of action of various anxiolytic drugs at the molecular level. Their mechanism of action often relates to the inhibitory neurotransmitter GABA and it might be speculated that GABA has a role in anxiety. Future research will concentrate on designing better anxiolytic drugs, based for example on the discovery of partial benzodiazepine receptor agonists, and also on GABA uptake inhibitors as enhancers of GABAergic function. Furthermore, scientific studies will focus on a search for putative biological defects related to anxiety, such as defects in the GABA/benzodiazepine receptor chloride channel complex.


Partial Agonist Chloride Channel Anxiolytic Drug GABAergic Neurotransmission Nipecotic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bennett DA, Amrick CL (1986) 2-Amino-7-phosphonoheptanoic acid (AP7) produces discriminative stimuli and anticonflict effects similar to diazepam. Life Sci 39: 2455–2461PubMedCrossRefGoogle Scholar
  2. Bræstrup C, Nielsen M (1983) Benzodiazepine receptors. In: Iversen L, Iversen DS, Snyder SH (eds) Handbook of psychopharmacology, vol 17. Plenum, New York, pp 285–384Google Scholar
  3. Bræstrup C, Honorè T, Nielsen M, Petersen EN, Jensen LH (1984) Ligands for benzodiazepine receptors with positive and negative efficacy. Biochem Pharmacol 33: 859–862PubMedCrossRefGoogle Scholar
  4. Collins P, Sakalis G, Minn FL (1976) Clinical response to a potential non sedative anxiolytic. Curr Ther Res 19: 512–515PubMedGoogle Scholar
  5. Costa E, Guidotti A, Mao CC, Suria A (1975) New concepts on the mechanism of action of benzodiazepines. Life Sci 17: 167–186PubMedCrossRefGoogle Scholar
  6. Dorow R, Horowski R, Paschelke G, Asmis M, Bræstrup C (1983) Severe anxiety induced by FG 7142, a β-carboline ligand for benzodiazepine receptors. Lancet 11: 98–99CrossRefGoogle Scholar
  7. Falch E, Christensen V, Jacobsen P, Bybjerg J, Krogsgaard-Larsen P (1984) Amanita muscaria in medicinal chemistry. I. Muscimol and related GABA agonists with anticonvulsant and central non-opioid analgesic effects. In: Krogsgaard-Larsen P, Christensen SB, Kofod H (eds) Natural products and drug development. Munksgaard, Copenhagen, pp 504–524Google Scholar
  8. Haefely W, Kulcsâr A, Moehler H, Pieri L, Pole P, Schaffner R (1975) Possible involvement of GABA in the central actions of benzodiazepines. In: Costa E, Greengard P (eds) Mechanism of action of benzodiazepines. Raven, New York, pp 131–151Google Scholar
  9. Hammond EJ, Wilder BJ (1985) Gamma-vinyl GABA. Gen Pharmacol 16: 441–447PubMedCrossRefGoogle Scholar
  10. Munkvad I, Randrup A, Fog R (1980) Amphetamines and psychosis. In: de Wied D, Nam Keep PA (eds) Hormones and the brain. MTP Press, Lancester, pp 221–229CrossRefGoogle Scholar
  11. Olsen RW (1981) GABAbenzodiazepine-barbiturate receptor interactions. J Neurochem 37: 1–13PubMedCrossRefGoogle Scholar
  12. Petersen EN, Lassen JB (1981) A water lick conflict paradigm using drug experienced rats. Psychopharmacology 75: 236–239PubMedCrossRefGoogle Scholar
  13. Redmond DE Jr (1986) The possible role of locus coeruleus noradrenergic activity in anxiety-panic. Clin Neuropharmacol 9: 40–42PubMedGoogle Scholar
  14. Riblet LA, Taylor DP, Eison MS, Stanton HC (1982) Pharmacology and neurochemistry of buspirone. J Clin Psychiatry 43: 11–16PubMedGoogle Scholar
  15. Rodin E (1958) Metrazol tolerance in a “normal” volunteer population. Electroencephalogr Clin Neurophysiol 10: 433–446PubMedCrossRefGoogle Scholar
  16. Younger LM, Fowler PJ, Zarevics P, Setler PE (1984) Novel inhibitors of γ-aminobutyric acid (GABA) uptake: anticonvulsant actions in rats. J Pharmacol Exp Ther 228: 109–115Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • C. Bræstrup
    • 1
  • E. B. Nielsen
    • 1
  1. 1.Pharmaceuticals R&DNOVO Industrial A/SBagsværdDenmark

Personalised recommendations